NASDAQ: CFRX Navigate ContraFect Corporation HOME ABOUT US TECHNOLOGY PIPELINE INVESTORS & MEDIA CAREERS CONTACT US Presentations Investors & Media Home Investors & Media Presentations Investors & Media OVERVIEW NEWS / EVENTS PRESENTATIONS COMPANY INFORMATION FINANCIAL INFORMATION ANALYST COVERAGE STOCK DATA SEC FILINGS CORPORATE GOVERNANCE Email Alerts Tear Sheet Contacts RSS News Feed CORPORATE PRESENTATIONS Corporate Presentation Published: October 18, 2021 2019 R&D Day Presentation Published: May 14, 2019 Audio Replay OTHER PRESENTATIONS Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens Published: July 19, 2021 Lysin CF-370 Exhibits Potent Bactericidal Activity Against Clinical MDR and XDR Pseudomonas aeruginosa Isolates Including Carbapenem and/or Colistin Resistant Forms Published: July 19, 2021 Synergistic anti-biofilm activity of exebacase and rifampin, vancomycin or daptomycin against Staphylococcus epidermidis strains responsible for bone and joint infections Published: July 19, 2021 Exebacase Reduced Length of Stay and 30-Day Readmission Rates for US Patients with MRSA Bacteremia Including Endocarditis Compared to Standard of Care Antibiotics Alone in a Phase 2 Study Published: October 3, 2019 PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase(CF-301) in Pre-Clinical Models ASM 2019, Outstanding Abstract Award Published: June 22, 2019 Exebacase (Lysin CF-301) Improved Clinical Responder Rates In Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia Including Endocarditis Compared To Standard Of Care Antibiotics (SOC) Alone In A First-in-Patient Phase 2 Study Published: April 16, 2019 Direct Lytic Agents: differentiated, first-in-class biologics for the treatment of life-threatening and drug-resistant infections Published: April 14, 2019 Bacteriophage-Derived Lysins Exert a Potent Bactericidal Effect Against Pseudomonas aeruginosa Published: February 26, 2019 Lysin CF-301 (Exebacase) Activates Latent Host Factors in Human Blood to Potentiate Bacteriolysis © 2021 ContraFect Corporation. All Rights Reserved. COPYRIGHT PRIVACY POLICY EXPANDED ACCESS POLICY DISCLAIMER SITE MAP LINKEDIN TWITTER